A personalized cancer vaccine has cleared a major hurdle. Merck and Moderna say the late-stage trial for their individualized mRNA cancer vaccine, code-named mRNA-4157 (V940), met its primary goal in patients with resected high-risk melanoma, showing the personalized shot slows or prevents the cancer from coming back. It is among the first Phase 3 wins for a truly personalized mRNA cancer treatment, and it changes the conversation about whether vaccines can fight cancer, not just infectious disease.
What the trial showed
The study hit its primary endpoint of recurrence-free survival, meaning patients on the vaccine-plus-combination arm lived longer without their melanoma returning than those who did not get it. It also cleared a secondary endpoint looking at time before metastatic lesions appeared elsewhere in the body, a signal that the therapy is not just delaying but redirecting the disease.
How the vaccine works
Unlike a conventional jab, mRNA-4157 is built to each patient’s tumor. After surgery removes the melanoma, scientists sequence the individual cancer’s mutations and design a messenger-RNA vaccine that trains the immune system to recognize and attack those specific neoantigens. In the trial it is paired with Merck’s immunotherapy Keytruda (pembrolizumab), a checkpoint inhibitor that keeps immune cells switched on.
| Step | What happens |
|---|---|
| Resect | Surgically remove the melanoma |
| Sequence | Map the tumor’s unique mutations |
| Design | Build an mRNA vaccine against those neoantigens |
| Treat | Give the vaccine with Keytruda to retrain the immune system |
Why this is a landmark
Personalized cancer vaccines have been a scientific promise for years, but proving them in a randomized late-stage trial in a solid tumor is the hardest step. Scientists had long doubted whether mRNA technology, which proved itself against COVID, could be aimed at each person’s cancer at scale. This result is the strongest evidence yet that it can, and it sets up a push toward regulatory approval for melanoma, a disease that returns in a meaningful share of high-risk patients.
The stakes beyond melanoma
The approval push matters because melanoma is a test case: the same platform is being studied across other cancers, and a win here bolsters the whole field. For Moderna the trial is the payoff of its long bet that mRNA could work beyond a pandemic, which is why its stock more than doubled on the news, the kind of fundamental catalyst that momentum stocks rarely get, and for Merck it deepens an oncology portfolio already built on Keytruda. The caveat, as ever with cancer data, is that favorable trial results still face years of regulatory review and real-world confirmation before a personalized vaccine reaches patients.
